Influenza News and Research

Latest Influenza News and Research

Firm sees drugs sales rising 5 to 7 percent next year, other drug industry news

The Associated Press reports that global prescription drug sales should rise 5 percent to 7 percent next year reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm IMS Health.

8 Oct 2010

Emergent BioSolutions and TLV form new joint venture to develop flu vaccines

Emergent BioSolutions Inc., a U.S.-based developer and manufacturer of vaccines and antibody therapies, today launched its Singapore operations.

8 Oct 2010

International scientific conference explores new approaches to prevent infectious diseases

Swine flu, cancer, bioterrorism and the latest trends in countermeasures to combat these life-threatening diseases and infections are among the topics to be discussed at the upcoming New Cells for New Vaccines V: Global Perspectives international scientific conference, on October 11-13 in Wilmington, Delaware, at the Hotel du Pont.

8 Oct 2010

Inviragen, PharmaJet awarded NIAID contract to develop needle-free, easy to administer dengue vaccine

Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the development of a needle-free, easy to administer dengue vaccine. The award will fund preclinical studies, regulatory filings, manufacturing and clinical testing of Inviragen's tetravalent dengue vaccine, DENVax delivered with PharmaJet's convenient needle-free injection device.

8 Oct 2010

Synthetic Genomics, JCVI announce formation of new company to develop next generation vaccines

The company Synthetic Genomics Inc. (SGI) and the not-for-profit research organization, the J. Craig Venter Institute (JCVI) today announced the formation of a new company, Synthetic Genomics Vaccines Inc. (SGVI).

7 Oct 2010

Johnson & Johnson to acquire all outstanding equity of Crucell for euro 1.75 billion

Johnson & Johnson and Crucell N.V. today announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately euro 1.75 billion in a recommended cash tender offer.

6 Oct 2010

Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1

Altravax, Inc. announced today that it has been awarded two SBIR grants totaling $1.2 million from the NIH's National Institute of Allergy and Infectious Diseases for research on antibody-inducing vaccines for HIV-1.

6 Oct 2010

Liquidia commences dosing in LIQ-001 Phase 1 trial for seasonal influenza

Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.

5 Oct 2010

Maternal influenza vaccination prevents flu in infants

Babies whose mothers who receive influenza vaccines while pregnant appear less likely to be infected with flu or hospitalized for respiratory illnesses in their first six months of life, according to a report posted online today that will appear in the February 2011 print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

5 Oct 2010

NIH to award $64M under Transformative Research Projects program

The National Institutes of Health will award up to $64 million over five years to encourage exploration of exceptionally innovative and original research ideas that have the potential for extraordinary impact.

4 Oct 2010

Medicago announces official groundbreaking ceremony for U.S. plant-based commercial grade vaccine facility

Medicago U.S.A. Inc., a wholly owned subsidiary of Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that company executives, along with U.S. Senator Kay Hagan (D-NC) and U.S. Congressman David Price (D-NC), are holding an official groundbreaking ceremony this morning for its U.S. plant-based commercial grade vaccine facility in Research Triangle Park, North Carolina.

1 Oct 2010

Healthy respect for flu this season

Flu season officially begins Friday, Oct. 1, and unlike last year's season when shortages lead to rationing, there will be plenty of vaccine on hand for everyone who wants a flu shot.

1 Oct 2010

Experts provide information on H1N1 and seasonal flu at Johns Hopkins hospital

Johns Hopkins has a wide range of experts available for interviews and comments about seasonal flu, H1N1, emergency preparedness, infection control, flu transmission in children, vaccine safety, flu treatment, public health ethics, flu in cancer patients, and related public communications strategies. If you would like to interview a Johns Hopkins expert, call or e-mail the designated information officer in the list below.

1 Oct 2010

Aethlon Medical engages Fabiani & Company to assist in establishment of federal partnerships

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has engaged Fabiani & Company to assist in the establishment of federal partnerships that advance biodefense, cancer, and chronic infectious disease applications of the Aethlon Hemopurifier®.

30 Sep 2010

First responders may not be willing to report for work if disaster is a potentially lethal pandemic

Although first responders willingly put themselves in harm's way during disasters, new research indicates that they may not be as willing- if the disaster is a potentially lethal pandemic.

30 Sep 2010

NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Inovio Pharmaceuticals and the University of Pennsylvania have received a grant of $3.1 million from the National Institutes of Health (NIH) Director's Office to further fund Inovio's universal SynCon™ flu vaccine development.

30 Sep 2010

Researchers develop genetic screening method to identify drug-resistant HCV strains

In recent human trials for a promising new class of drug designed to target the hepatitis C virus (HCV) without shutting down the immune system, some of the HCV strains being treated exhibited signs of drug resistance.

30 Sep 2010

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Baxter International Inc. today announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES). The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults and the elderly. PREFLUCEL is manufactured using Baxter's proprietary advanced Vero cell technology.

From Baxter International Inc. 30 Sep 2010

Swine flu no longer a threat to Americans: Report

According to the latest research most Americans are immune to the swine flu virus. Results of the study by the National Institute of Allergy and Infectious Diseases, published in the journal mBio show that around 59 percent of the 310 million U.S. population has developed immunity to H1N1 either from exposure to similar viruses, vaccination, or natural H1N1 infection.

29 Sep 2010

Quidel receives FDA clearance for QuickVue RSV 10 immunoassay test

Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its QuickVue RSV 10, a lateral flow immunoassay test for the qualitative detection of acute respiratory syncytial virus (RSV) infections.

29 Sep 2010

Influenza News and Research

Latest Influenza News and Research

Firm sees drugs sales rising 5 to 7 percent next year, other drug industry news

Emergent BioSolutions and TLV form new joint venture to develop flu vaccines

International scientific conference explores new approaches to prevent infectious diseases

Inviragen, PharmaJet awarded NIAID contract to develop needle-free, easy to administer dengue vaccine

Synthetic Genomics, JCVI announce formation of new company to develop next generation vaccines

Johnson & Johnson to acquire all outstanding equity of Crucell for euro 1.75 billion

Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1

Liquidia commences dosing in LIQ-001 Phase 1 trial for seasonal influenza

Maternal influenza vaccination prevents flu in infants

NIH to award $64M under Transformative Research Projects program

Medicago announces official groundbreaking ceremony for U.S. plant-based commercial grade vaccine facility

Healthy respect for flu this season

Experts provide information on H1N1 and seasonal flu at Johns Hopkins hospital

Aethlon Medical engages Fabiani & Company to assist in establishment of federal partnerships

First responders may not be willing to report for work if disaster is a potentially lethal pandemic

NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development

Researchers develop genetic screening method to identify drug-resistant HCV strains

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Swine flu no longer a threat to Americans: Report

Quidel receives FDA clearance for QuickVue RSV 10 immunoassay test

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Influenza News and Research

Latest Influenza News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in